)
Visual
test
Gland Pharma
Gland Pharma (GLAND) investor relations material
Gland Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary28 Jan, 2026
Executive summary
Q3 FY26 revenue grew 22% YoY to INR 1,695.4 crore, with strong gains across businesses, including Cenexi, and 37% adjusted PAT growth, driven by US and Europe markets and new product launches.
Adjusted EBITDA rose 25% YoY to INR 449 crore, with margin expansion and improved profitability.
Cenexi delivered EUR 50 million in Q3 revenue (+39% YoY), positive EBITDA, and margin improvement from cost initiatives and capacity ramp-ups.
Growth was driven by new product launches, CDMO contract ramp-ups, and increased capacity utilization.
Strategic focus remains on innovation-led CDMO, specialty injectables, and significant CapEx for expansion.
Financial highlights
Q3 FY26 consolidated revenue: INR 1,695.4 crore (₹16,954 million), up 22% YoY; 9M FY26: INR 4,687.9 crore (₹46,879 million), up 12% YoY.
Adjusted EBITDA for Q3: INR 449 crore (₹4,490 million, 26% margin), up 25% YoY; 9M: INR 1,158.2 crore (₹11,582 million, 25% margin), up 26% YoY.
Adjusted PAT for Q3: INR 279.7 crore (₹2,797 million, 16% margin), up 37% YoY; 9M: INR 678.9 crore (₹6,789 million, 14% margin), up 33% YoY.
Gross margin for Q3: 66%; 9M: 65%, up from 62% last year.
R&D expenses in Q3 FY26 were ₹650 million (5.4% of revenue), up from ₹437 million (4.3%) in Q3 FY25.
Outlook and guidance
Confident in sustaining momentum with upcoming launches, CDMO contract ramp-ups, and new capacities.
Five-year CapEx plan of INR 2,000 crore for brownfield expansions, BFS, and ophthalmic lines; FY26 CapEx for base business at INR 250 crore, Cenexi at EUR 25 million.
FY27 base business growth expected at 12%-13%, with potential upside from faster regulatory approvals.
Five-year organic CAGR target of 15%.
Commercialization of co-development pipeline anticipated to begin in FY28.
Cenexi's breakeven and margin profile improvement
Detail DDC capacity expansion and new areas
New CMO contract's revenue visibility?
GLP-1 capacity utilization in FY28?
Cenexi's ROCE and EBITDA margin goals?
How does CapEx support value-led growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- PRIC
Record Q4 order intake, new contracts, and improved cash flow despite lower sales and profits. - ENSI
Record revenue growth, positive EBITDA, and strong outlook with cash flow positivity expected by end-2026. - DWNI
Stable rental growth, Care segment sale, and positive 2025 outlook despite lower EBT. - JUBLINGREA
Volume growth in specialty and nutrition offset pricing headwinds; net debt down 20% YoY. - TRI
Strong organic growth, margin expansion, and capital returns set the stage for 2026 targets. - RUG
Record Q4 growth, higher margins, and a SEK 5.00 dividend highlight strong performance. - HSY
2026 outlook targets 4%-5% sales growth, margin recovery, and strong EPS rebound. - CMI
Strong 2025 results, $458M Accelera charges, and 2026 guidance targets growth and margin stability. - BLACKBUCK
Q3 FY26 delivered 53% YoY revenue growth and a return to profit, led by core and new segments. - KKR
Record earnings, AUM growth, and new sports investing platform drive strong 2025 results.
Next Gland Pharma earnings date
Q4 202620 May, 2026
Gland Pharma
Next Gland Pharma earnings date
Q4 202620 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Gland Pharma Limited manufactures and markets injectable pharmaceutical products. Its product portfolio includes vials, pre-filled syringes, and infusion bags, primarily for hospital and clinical use. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage